isavuconazole has been researched along with Chromoblastomycosis* in 3 studies
3 other study(ies) available for isavuconazole and Chromoblastomycosis
| Article | Year |
|---|---|
[Treatment of chromoblastomycosis and phaeohyphomycosis].
Cases of chromoblastomycosis are frequent in certain parts of the world, especially in some developing countries. Clinical manifestations of chromoblastomycosis are typical. To a certain extent, pathogens causing chromoblastomycosis overlap with those causing phaeohyphomycosis. Although cases of phaeohyphomycosis are not very common, they may end fatally. Therefore early management of these life-threatening infections is rather important. Targeted antifungal therapy and surgery are effective in combating these infections. Recently, several triazole antifungals such as posaconazole and isavuconazole have been available to treat even the most severe cases. Prevention of the infection should be aimed at reducing the risk of subcutaneous trauma, particularly in persons in contact with potential sources of infection such as wood materials important from endemic areas. Topics: Antifungal Agents; Chromoblastomycosis; Humans; Nitriles; Phaeohyphomycosis; Pyridines; Triazoles | 2020 |
In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.
A global collection of Cladophialophora carrionii strains (n = 81) was tested against nine antifungal drugs. MIC90s of all strains were as follows in increasing order: itraconazole and posaconazole, 0.063 μg/ml; terbinafine, 0.125 μg/ml; isavuconazole and voriconazole, 0.25 μg/ml; caspofungin, 2 μg/ml; micafungin, 4 μg/ml; amphotericin B, 8 μg/ml; and fluconazole, 64 μg/ml. Topics: Amphotericin B; Antifungal Agents; Ascomycota; Caspofungin; Chromoblastomycosis; Echinocandins; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Nitriles; Pyridines; Pyrimidines; Triazoles; Voriconazole | 2013 |
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
The in vitro activities of eight antifungal drugs against clinical isolates of Fonsecaea pedrosoi (n = 21), Fonsecaea monophora (n = 25), and Fonsecaea nubica (n = 9) were tested. The resulting MIC(90)s for all strains (n = 55) were as follows, in increasing order: posaconazole, 0.063 microg/ml; itraconazole, 0.125 microg/ml; isavuconazole, 0.25 microg/ml; voriconazole, 0.5 microg/ml; amphotericin B, 2 microg/ml; caspofungin, 2 microg/ml; anidulafungin, 2 microg/ml; and fluconazole, 32 microg/ml. Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Ascomycota; Caspofungin; Chromoblastomycosis; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; In Vitro Techniques; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Nitriles; Pyridines; Pyrimidines; Triazoles; Voriconazole | 2010 |